心血管病防治知识(下半月)
心血管病防治知識(下半月)
심혈관병방치지식(하반월)
XINXUEGUANBING FANGZHI ZHISHI
2014年
10期
48-50
,共3页
波利维%泰嘉%治疗效果%冠心病%经济性
波利維%泰嘉%治療效果%冠心病%經濟性
파리유%태가%치료효과%관심병%경제성
Plavix%Techno%Efficacy%Coronary heart disease%Economic efficiency
目的对比分析应用波利维和泰嘉治疗冠心病的临床疗效和药物经济性,为日后临床用药提供依据。方法回顾分析从2012年6月到2013年6月期间我院收治的冠心病患者者66例。将66例患者按入院日期随机分为波利维组和泰嘉组。波利维患者(n=33)采用波利维治疗冠心病,泰嘉患者(n=33)采用泰嘉治疗。比较两组患者的治疗效果、术后12周血液学检查、不良不应和治疗费用。结果1年内,波利维组的心血管不良事件(MACE)发生率效率为9.09%。泰嘉的心血管不良事件(MACE)发生率效率为12.12%,组患者的治疗效果无显著性差异(P>0.05)。术后12周血液学检查两组间无显著性差异(P>0.05)。部分患者发生血小板减少、皮疹、上腹部不适等不良反应,两组间的不良反应无显著性差异(P>0.05)。但在一年内,采用波利维控制病情平均需要(7258.62±980.50)元,而采用泰嘉控制病情只需要(4642.50±1020.56),组间有显著性差异(P<0.05)。结论进口药品波利维和国产的泰嘉在治疗冠心病的疗效上无差别,采用国产的泰嘉更为经济。
目的對比分析應用波利維和泰嘉治療冠心病的臨床療效和藥物經濟性,為日後臨床用藥提供依據。方法迴顧分析從2012年6月到2013年6月期間我院收治的冠心病患者者66例。將66例患者按入院日期隨機分為波利維組和泰嘉組。波利維患者(n=33)採用波利維治療冠心病,泰嘉患者(n=33)採用泰嘉治療。比較兩組患者的治療效果、術後12週血液學檢查、不良不應和治療費用。結果1年內,波利維組的心血管不良事件(MACE)髮生率效率為9.09%。泰嘉的心血管不良事件(MACE)髮生率效率為12.12%,組患者的治療效果無顯著性差異(P>0.05)。術後12週血液學檢查兩組間無顯著性差異(P>0.05)。部分患者髮生血小闆減少、皮疹、上腹部不適等不良反應,兩組間的不良反應無顯著性差異(P>0.05)。但在一年內,採用波利維控製病情平均需要(7258.62±980.50)元,而採用泰嘉控製病情隻需要(4642.50±1020.56),組間有顯著性差異(P<0.05)。結論進口藥品波利維和國產的泰嘉在治療冠心病的療效上無差彆,採用國產的泰嘉更為經濟。
목적대비분석응용파리유화태가치료관심병적림상료효화약물경제성,위일후림상용약제공의거。방법회고분석종2012년6월도2013년6월기간아원수치적관심병환자자66례。장66례환자안입원일기수궤분위파리유조화태가조。파리유환자(n=33)채용파리유치료관심병,태가환자(n=33)채용태가치료。비교량조환자적치료효과、술후12주혈액학검사、불량불응화치료비용。결과1년내,파리유조적심혈관불량사건(MACE)발생솔효솔위9.09%。태가적심혈관불량사건(MACE)발생솔효솔위12.12%,조환자적치료효과무현저성차이(P>0.05)。술후12주혈액학검사량조간무현저성차이(P>0.05)。부분환자발생혈소판감소、피진、상복부불괄등불량반응,량조간적불량반응무현저성차이(P>0.05)。단재일년내,채용파리유공제병정평균수요(7258.62±980.50)원,이채용태가공제병정지수요(4642.50±1020.56),조간유현저성차이(P<0.05)。결론진구약품파리유화국산적태가재치료관심병적료효상무차별,채용국산적태가경위경제。
Objective To compare the therapeutic efficacy and economic efficiency of Plavix and Techno in patients with coronary heart disease, and to provide a basis for future clinical application. Methods A retrospective study was performed on 66 patients with coronary heart disease admitted to our hospital from June 2012 to June 2013. These patients were randomly divided into Plavix group and Techno group according to their admission dates. Patients in the Plavix (n =33) and Techno (n =33) groups were treated with Plavix and Techno, respectively. A hematological examination was performed and adverse reactions were recorded for each patient at 12 weeks after the treatment. Efficacy in both groups was compared in a 1 -year follow-up. The cost for each treatment was also analyzed. Results The incidence rates of major adverse cardiac events in the Plavix and Techno groups were 9.09% and 12.12%, respectively, in the 1-year follow -up, and there was no significant difference between the two groups (P>0.05). In addition, no significant difference in results of the hematological examination was observed between the two groups at 12 weeks after the treatment (P>0.05). Although adverse reactions such as thrombocytopenia, rash, and abdominal discomfort were confirmed in some patients, there was no significant difference between the two groups (P>0.05). However, the 1-year cost of treatment in the Plavix group (7258.62±980.50)RMB was significantly higher than that in the Techno group (4642.50±1020.56)RMB (P<0.05). conclusion There is no significant difference in efficacy between the imported drug Plavix and the domestic drug Techno in patients with coronary heart disease, whereas Techno has a much higher economic efficiency than Plavix, and thus should be widely used in the clinical treatment of coronary heart disease.